Embecta (NASDAQ:EMBC) Cut to “Buy” at Wall Street Zen

Embecta (NASDAQ:EMBC) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Friday.

A number of other research analysts have also commented on EMBC. BTIG Research reissued a “buy” rating on shares of Embecta in a report on Tuesday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, October 8th. Finally, Zacks Research lowered Embecta from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. One research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $19.00.

Embecta Trading Up 1.4%

EMBC opened at $12.75 on Friday. The stock’s fifty day simple moving average is $13.92 and its 200 day simple moving average is $12.49. Embecta has a 1-year low of $9.20 and a 1-year high of $21.48. The stock has a market cap of $745.94 million, a PE ratio of 7.82, a price-to-earnings-growth ratio of 0.70 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Tuesday, November 25th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.46 by $0.04. The firm had revenue of $263.30 million for the quarter, compared to the consensus estimate of $265.66 million. Embecta had a net margin of 8.83% and a negative return on equity of 24.62%. The company’s quarterly revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.45 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts forecast that Embecta will post 2.85 earnings per share for the current year.

Institutional Trading of Embecta

Institutional investors have recently modified their holdings of the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Embecta by 7.9% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,005 shares of the company’s stock worth $145,000 after purchasing an additional 1,093 shares during the period. The Manufacturers Life Insurance Company lifted its position in Embecta by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company’s stock worth $209,000 after purchasing an additional 1,110 shares during the period. CWM LLC grew its stake in Embecta by 16.0% during the second quarter. CWM LLC now owns 8,080 shares of the company’s stock worth $78,000 after buying an additional 1,115 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Embecta by 2.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock valued at $629,000 after buying an additional 1,159 shares during the period. Finally, SummerHaven Investment Management LLC raised its position in shares of Embecta by 1.9% in the 2nd quarter. SummerHaven Investment Management LLC now owns 66,313 shares of the company’s stock valued at $643,000 after buying an additional 1,268 shares in the last quarter. 93.83% of the stock is currently owned by institutional investors.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.